Trial Profile
Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 03 Aug 2020 Results published in the Journal of Clinical Endocrinology and Metabolism
- 27 Mar 2020 Results examining the effect of combination therapy with canagliflozin plus liraglutide on HbA1c, endogenous glucose production (EGP), and body weight versus each therapy alone, published in the Diabetes Care
- 19 Apr 2019 Status changed from active, no longer recruiting to completed.